Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home

Holger Müller

CEO & Co-Founder

ProVascTec

Cork, Ireland

34 profile visits

I am the CEO of ProVascTec, a cell therapy company that combines biomedical engineering with cell therapies to enable intracorporal precision delivery of cells

My organisation

ProVascTec

ProVascTec

SME

Cork, Ireland

We are a team of cell biologists, medical doctors, and entrepreneurs, with a vision to enable the delivery of a cellular payload to any site of medical need. Past attempts to broadly apply cell therapies have failed to deliver. Key obstacles have been the absence of scalable allogeneic cell sources, effective cell delivery, payload size, and rapid cells death upon delivery. Our solution aims to be the first breakthrough therapy combining cells with a biodegradable device that can be delivered through the vasculature to any site in the body. Moreover, specific design modifications would allow similar biodegradable devices to be delivered by minimally invasive endoscopic approaches to any organ in the body including in the broad fields of inflammation, cancer and other age related diseases.
Read more

About me

I am the CEO and co-founder of ProVascTec. Following an education in chemistry, which concluded with a PHD from the Swiss Federal Institute of Technology, Holger started his professional career at Bain & Company, a leading international strategic management consultancy. He later joined Novartis, where he was leading several innovation projects at various stages of the product lifecycle. Following a 10 year career at Novartis, Holger joined Cell Medica as SVP Commercial Operations, a cell therapy company focused on immunological- and hematological applications. Subsequently, Holger held additional c-level positions at startup companies in Switzerland before joinging ProVascTec in 2013.

Social media

Marketplace (1)

  • Project cooperation

    Development of a biodegradable stent like scaffold

    Stents have become staples in angioplasty procedures. ProVascTec intends to develop a biodegradable stent-type scaffold for use in PVT1812

    • Early
    • Research
    • Technical
    • Healthcare
    • EU projects
    • Biotech, Pharma and Cosmetics
    • Partner looking for consortium
    Author

    Holger Müller

    CEO & Co-Founder at ProVascTec

    Cork, Ireland